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The Wisconsin Antibiotic Resistance Network (WARN)
was launched in 1999 to educate physicians and the public
about judicious antimicrobial drug use. Public education
included radio and television advertisements, posters,
pamphlets, and presentations at childcare centers.
Physician education included mailings, susceptibility
reports, practice guidelines, satellite conferences, and pre-
sentations. We analyzed antimicrobial prescribing data for
primary care physicians in Wisconsin and Minnesota (con-
trol state). Antimicrobial prescribing declined 19.8% in
Minnesota and 20.4% in Wisconsin from 1998 to 2003.
Prescribing by internists declined significantly more in
Wisconsin than Minnesota, but the opposite was true for
pediatricians. We conclude that the secular trend of declin-
ing antimicrobial drug use continued through 2003, but a
large-scale educational program did not generate greater
reductions in Wisconsin despite improved knowledge.
State and local organizations should consider a balanced
approach that includes limited statewide educational activ-
ities with increasing emphasis on local, provider-level inter-
ventions and policy development to promote careful
antimicrobial drug use.
A
ntimicrobial drug–resistant strains of community-
acquired pathogens, including Streptococcus pneumo-
niae and Staphylococcus aureus, have emerged as serious
global health threats (1–3). Multiple studies have demon-
strated a strong and consistent link between antimicrobial
drug use and antimicrobial resistance at both individual
and population levels (4–9). Despite this link, inappropri-
ate and ineffective use of antimicrobial agents for viral res-
piratory infections is common (10–16). In 1998, the
Institute of Medicine issued a workshop report that
addressed the growing problem of antimicrobial drug
resistance and potential strategies to prolong the effective-
ness of existing drugs (17). The report found that physi-
cians and patients have not received adequate information
about the appropriate use of antimicrobial drugs and the
short- and long-term risks of overuse. Several approaches
were suggested, including multifaceted clinician educa-
tion, clinical practice protocols, feedback on local resist-
ance trends, patient-oriented educational materials, and
use of popular media for public education. 
We describe the activities and impact of a 5-year, mul-
tifaceted educational campaign to reduce outpatient
antimicrobial drug prescribing in Wisconsin. The
Wisconsin Antibiotic Resistance Network (WARN) was
launched in 1999 as a federally funded demonstration proj-
ect to educate primary care physicians and the public about
drug resistance and judicious antimicrobial drug use.
Antimicrobial drug prescribing rates were assessed annu-
ally and compared to Minnesota prescribing rates, where
educational activities were limited before 2002.
Methods
WARN Organization
WARN was established as a collaborative project
involving the Marshfield Clinic Research Foundation,
Wisconsin Medical Society, and Wisconsin Division of
Public Health. The Wisconsin Medical Society collaborat-
ed with the Marshfield Clinic Research Foundation to
develop the public education campaign, and the latter
organization was responsible for data collection and eval-
uation. The Division of Public Health assisted with
program planning and collected invasive pneumococcal
isolates for susceptibility testing. 
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gram managers and 2 health educators. Representatives of
each position were based in Madison and in Marshfield to
cover the southern and northern parts of the state. An advi-
sory board was established with representation from man-
aged care organizations, employers, local public health
agencies, primary care practices, infectious disease
experts, childcare centers, pharmacists, and the Centers for
Disease Control and Prevention. Campaign themes, char-
acters, messages, and print materials were developed dur-
ing the first year (1999). An expert panel was convened to
develop local clinical practice guidelines for acute respira-
tory illness in Wisconsin. Educational needs were assessed
through surveys of primary care clinicians and the general
public (18). Limited public and physician educational
activities were initiated in 2000, and the program was
implemented in full from 2001 to 2003. Educational inter-
ventions were designed to be multifaceted and consistent
with behavioral research that suggested a need for a vari-
ety of educational strategies with repetitive and reinforcing
messages (19–21). 
Public and Physician Education
The tag lines for the public education campaign were
“There’s no excuse for overuse!” and “Get smart about
antibiotics!” The campaign mascots, Annie Biotic and
Moxie Cillin, were cartoon characters designed to appeal
largely to children and parents. Public education materials
included posters, brochures, stickers, coloring sheets, mag-
nets, and disease-specific parent handouts (Table 1). All
materials were available free of charge to healthcare
providers, clinics, and community organizations. Spanish
translations were also available for many of the written
materials. A Web site was established through the
Wisconsin Medical Society to describe WARN activities
and facilitate ordering materials. The distribution volume
for WARN educational materials is shown in Table 2.
Outreach to childcare centers was a major focus of com-
munity education because children attending group child
care have high rates of respiratory illness. Annual mailings
were sent to >5,000 licensed childcare centers, and on-site
presentations were given at 170 centers. Additional presen-
tations were made at childcare conferences and in college
classes on early childhood education. Physician-education
activities began in 2000 and included direct mailings with
samples of WARN materials, development and distribution
of guidelines for judicious antibiotic use, satellite broad-
casts, dissemination of pneumococcal antimicrobial resist-
ance data, and professional presentations (Table 1). 
Media Campaign
The media campaign included paid advertising and
strategies to maximize coverage. The campaign was
launched with a press conference in 1999, followed by
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bial resistance issues from 2000 through 2003 (Table 1).
This coverage included newspaper reports in Milwaukee,
Madison, and multiple smaller communities, as well as
local television news stories in Milwaukee, Madison, and
Wausau. Paid advertising was initiated on radio stations
broadcasting throughout the state and on television sta-
tions. Because of the high cost, television advertisements
were limited to periods of 2 to 4 weeks during the peak
respiratory illness season.
Research Design and Outcome Measures
Multiple evaluation components were developed to
measure the effect of the WARN educational campaign.
The major outcome for this report was annual antimicro-
bial drug use, measured by the number of primary care
prescriptions and the volume of retail antimicrobial drug
sales.
During the late 1990s, a national secular trend of
declining antimicrobial drug use occurred (22–24). To dis-
tinguish the impact of WARN from the secular trend,
antimicrobial drug–prescribing measures were obtained
for both Wisconsin and Minnesota. Although Minnesota is
not representative of the entire country, the use of a com-
parison state provided the opportunity to distinguish inter-
vention-related changes from regional trends in use that
were unrelated to the intervention. Minnesota was chosen
for geographic proximity and similarity in terms of popu-
lation size and ethnic distribution. Before 2002, patient
educational activities in Minnesota were limited. A group
of 6 Minnesota managed care plans distributed ≈17,000
cough and cold kits to patients during the 2000–2001 res-
piratory illness season, and 31,000 kits during the
2001–2002 season. An article promoting appropriate
antimicrobial drug use was published in the April 2001
issue of Minnesota Medicine (25), but no other formal pro-
grams to educate Minnesota physicians on appropriate
antimicrobial drug use were implemented until late 2002,
when sample materials (posters, buttons, “prescription
pads” for symptomatic therapy) were mailed to managers
at 377 Minnesota clinics and urgent care centers. 
Measures of Antimicrobial Drug Use
Prescribing data and retail volume distribution data
(measuring retail sales) were obtained from a commercial
source (IMS Health, Inc., Plymouth Meeting, PA, USA)
for the states of Wisconsin and Minnesota. Physician pre-
scribing data were available for 1998 and 2000 through
2003. Prescribing and volume distribution data were not
available for individual drugs within each class. The
source data did not include any information regarding the
specific diagnosis or patient characteristics.
The prescribing databases included only new outpatient
prescriptions, and they were derived from transactional
data provided by 59% of all retail pharmacies in Wisconsin
and Minnesota. Approximately 65% of chain pharmacies
and 51% of independent retail pharmacies contributed raw
prescribing data. Prescriptions from unsampled stores
were estimated on the basis of prescription totals from
matched nearby stores, with weighting to adjust for differ-
ences in total retail sales volume, which was available for
nearly all stores. Estimates were also weighted to account
for the distance between sampled stores and matched
unsampled stores, with closer stores contributing more to
the estimated prescription volume. The proportion of all
prescriptions in each state that were based on estimated
data from unsampled stores was 33%–37%.
Physician-level prescribing data included data for all
licensed physicians with any of the following primary spe-
cialty codes: family (and general) practice, internal medi-
cine, pediatrics, or emergency medicine. Physicians were
classified geographically as practicing within or outside of
the largest metropolitan statistical area in each state. These
2 metropolitan statistical areas were Milwaukee-Waukesha
(4 counties) and Minneapolis-St. Paul (11 counties).
Retail volume distribution was determined by the vol-
ume of antimicrobial drugs distributed to retail outlets on
a monthly basis from 1999 to 2002. This distribution was
derived from an independent data source relative to the
physician-level prescribing data. Retail distribution data
(measured in kilograms) were reported by wholesalers and
distributors serving pharmacies in both states. Retail vol-
ume was not linked to specific prescriptions or providers
and therefore represented a measure of total outpatient
antimicrobial drug use in each state. Volume was based on
distribution to retailers rather than actual sales to patients,
and distributed drugs could be returned to wholesalers
without being sold. In this situation, returned drugs were
subtracted from the total distributed in a given month to
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Inpatient pharmacies, prisons, veterinary offices, nursing
homes, dialysis clinics, and federal government sites were
excluded from the volume distribution data. The retail vol-
ume sales database captured 93% of actual antimicrobial
drug distribution in Wisconsin and Minnesota. Volume
sales were divided by the annual population estimates in
each state and reported as grams per capita.
The following product groups were included in the
assessment of outpatient prescribing and retail volume
sales: amoxicillin/penicillin, amoxicillin-clavulanate,
cephalosporins, macrolides, extended-spectrum macro-
lides (azithromycin, clarithromycin), fluoroquinolones,
tetracyclines, trimethoprim-sulfamethoxazole, and other
sulfa drugs (including erythromycin/sulfisoxazole). Solid
and liquid formulations were reported separately, and liq-
uid formulations were used as surrogates for pediatric pre-
scribing. Broad-spectrum antimicrobial drugs were also
analyzed separately. Although no standard definition of
broad spectrum antimicrobial drugs exists, a previous
report on national trends in antimicrobial drug use classi-
fied the following groups as broad-spectrum: extended-
spectrum macrolides, fluoroquinolones, second- and
third-generation cephalosporins, and amoxicillin-clavu-
lanate (23). We used the same classification with 1 excep-
tion. In this study we classified all cephalosporins as
broad-spectrum because we were unable to distinguish
first-, second-, and third-generation cephalosporins.
Prescriber Cohort
A cohort of primary care physicians was established to
monitor and compare longitudinal trends in prescribing
antimicrobial drugs. The cohort was defined as primary
care physicians in Minnesota and Wisconsin who pre-
scribed at least 1 antimicrobial drug in each month during
the baseline year (1998) and each of the follow-up years
(2000–2003). This criterion was used to avoid including
residents and other physicians in temporary practice set-
tings. It also avoided including nonpractice time in pre-
scribing rate calculations, since information on individual
practice patterns was not available. The annual antimicro-
bial prescribing rate was calculated by dividing the num-
ber of new, filled prescriptions by the number of
physicians in the cohort.
The original 1998 prescriber database included 9,164
primary care physicians in Minnesota or Wisconsin who
prescribed any antimicrobial drug. Of those, 4,115 (45%)
prescribed >1 antimicrobial drug per month in 1998 and
annually from 2000 through 2003. This group made up the
final cohort for analysis of longitudinal prescribing trends.
A secondary analysis of prescribing trends was performed
based on the larger group of primary care physicians (n =
12,790) who prescribed >1 antimicrobial drugs during any
of the follow-up years but who were not necessarily in
continuous practice. 
Statistical Analysis
Prescribing rates for the 4,115 physicians in practice
throughout the study period were computed as the number
of antimicrobial prescriptions in a given year divided by
the number of physicians. Prescribing rates were therefore
equivalent to the mean number of prescriptions for antimi-
crobial drugs per physician each year. Population-based or
patient-based prescribing rates could not be calculated
because the populations served by the prescribing cohort
were undefined. To compare prescribing rates for each
year of the intervention period (2000–2003) to baseline
(1998), we fit Poisson regression models. Generalized esti-
mating equations (GEE) were employed to account for
within-physician correlation (26). An autoregressive work-
ing correlation structure was specified in the Poisson-GEE
models, and appropriate steps were taken to accommodate
the absence of data for calendar year 1999. Statistical com-
parisons of changes in rates in Wisconsin versus those in
Minnesota were derived from these models. 
Differences in baseline antimicrobial prescribing were
addressed by fitting additional Poisson-GEE models using
data from the intervention period with the natural log of
the baseline number of antimicrobial drug prescriptions
included as an independent variable. Prescribing rates per
physician-month were computed when analyzing the
12,790 physicians who wrote such prescriptions in >1
month of the study period. Months where a physician
wrote at least 1 prescription for an antimicrobial drug were
included in the denominators of rates (i.e., a physician was
assumed not to be in practice in months when he did not
write any such prescriptions). Per capita antimicrobial
drug sales were calculated based on annual population esti-
mates (www.census.gov). Analyses were completed by
using the SAS software (SAS Institute Inc., Cary, NC,
USA).
Results
The 4,115 primary care physicians in long-term prac-
tice included 2,009 (49%) in Minnesota and 2,106 (51%)
in Wisconsin. The proportion of physicians in family prac-
tice was higher in Wisconsin, and the proportion in inter-
nal medicine was higher in Minnesota (Table 3). During
1998, these physicians generated 1.5 million prescriptions
for antimicrobial drugs in each state, and the crude antimi-
crobial prescribing rate was nearly identical across states.
From 2000 through 2003, the prescribing rate for antimi-
crobial drugs in both states gradually declined (Figure 1).
From 1998 to 2003, the antimicrobial prescribing rate was
reduced by 19.8% in Minnesota and by 20.4% in
Wisconsin. The percentage reduction was 19.5% and
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included the 12,790 primary care physicians who pre-
scribed antimicrobial drugs at any time during the follow-
up period.
Retail sales of antimicrobial drugs (grams per capita)
declined by 27.4% in Minnesota and 17.3% in Wisconsin
from 1999 through 2002 (Figure 1). Sales of amoxicillin
and penicillin exceeded those of other product groups in
each year and accounted for 37% of all retail antimicrobial
distribution. In both states, retail sales of fluoroquinolones
remained level, and sales of amoxicillin-clavulanate
increased. Sales of most other product groups declined by
15% or more.
Stratification of antimicrobial prescribing rates by spe-
cialty showed that the reduction in prescribing differed
only for physicians in internal medicine and pediatrics
(Table 4). Antimicrobial prescribing declined more in
Wisconsin than Minnesota among internal medicine physi-
cians, but the opposite was true for pediatricians. In
Minnesota, the reduction in antimicrobial use was similar
for physicians practicing in the Minneapolis-St. Paul met-
ropolitan statistical area and those practicing elsewhere in
the state (Table 5). In Wisconsin, the reduction in antimi-
crobial prescribing was much less in the Milwaukee-
Waukesha metropolitan statistical area than in the
remainder of the state. Antimicrobial prescribing declined
significantly more in the Minneapolis-St. Paul metropoli-
tan statistical area than in the corresponding Milwaukee-
Waukesha area.
Prescriptions for liquid antimicrobial drugs (a surrogate
for pediatric use) declined 29% in Wisconsin and 32% in
Minnesota from 1998 to 2003 (p = 0.17). Prescriptions for
solid formulations declined 15%–17% in each state. The
percentage of prescriptions for broad-spectrum agents was
unchanged (within 2%) in each state from 1998 through
2003.
Regression models were fit to compare prescribing
rates in Wisconsin and Minnesota during each year from
2000 to 2003, with adjustment for specialty and baseline
prescribing in 1998. Two separate models were generated.
The first included physicians practicing in the
Minneapolis-St. Paul metropolitan statistical area or the
Milwaukee-Waukesha metropolitan statistical area. The
second included physicians practicing in other counties of
Minnesota or Wisconsin. In the latter model, the prescrib-
ing rate ratio was <1 in 2002 and 2003, indicating that,
when the 2 largest metropolitan areas were excluded,
Wisconsin physicians had significantly lower prescribing
rates than those in Minnesota (Figure 2). In contrast, the
prescribing rate ratio was >1 in each year within the 2
largest metropolitan areas, indicating that physicians in the
Milwaukee-Waukesha MSA had higher prescribing rates
than those in the Minneapolis-St. Paul MSA, after adjust-
ing for specialty and baseline prescribing.
Discussion
WARN represents the largest program on appropriate
antimicrobial drug use that has been evaluated to measure
the effect on prescribing. Previously published studies
demonstrated that interventions at the level of the physi-
cian, clinic, or community had a modest effect on prescrib-
ing (20,27–32). These focused programs are useful in
evaluating specific intervention strategies in a relatively
controlled setting. However, adoption of new practices
may be slow even when the intervention is proven to be
effective, and generalizability to larger populations may be
limited. In contrast, large-scale programs can reach physi-
cians and the general public in an entire state or large met-
ropolitan area. The development of WARN reflected a
need to implement and evaluate a large-scale demonstra-
tion project that could influence antimicrobial prescribing
throughout Wisconsin in a relatively short time. At the
time WARN was conceived and funded, knowledge of
national trends in antimicrobial prescribing was limited,
but we now know that prescribing declined substantially
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Figure 1. Temporal trends in per capita antimicrobial drug sales
and the mean number of prescriptions per physician in Minnesota
and Wisconsin.for both pediatric and adult populations in the 1990s
(22–24,33).
Outpatient antimicrobial use declined substantially in
both Wisconsin and Minnesota from 1998 to 2003, and no
additional intervention-related effect was apparent in
Wisconsin. Secondary analyses by specialty and practice
location demonstrated variable reductions in prescribing of
antimicrobial drugs, but to what extent these reductions
were related to WARN interventions, as opposed to other
factors that may be influencing secular trends, is unclear.
The potential effect of these other factors is illustrated by
the observation that Minnesota pediatricians improved
their prescribing practices more than Wisconsin pediatri-
cians, despite the absence of an organized, large-scale pro-
gram to improve pediatric prescribing in Minnesota. 
We found that changes in antimicrobial drug use were
less pronounced in the Milwaukee-Waukesha metropolitan
area than in other regions of Wisconsin. This finding con-
trasts with findings in Minnesota, where the decrease in
antimicrobial drug use in the Minneapolis-St. Paul metro-
politan area was similar to that in the rest of the state.
When these large metropolitan areas were excluded from
the analysis, prescribing of antimicrobial drugs decreased
more in Wisconsin than in Minnesota. Several factors may
have contributed to the relatively low impact of WARN in
the Milwaukee area. These factors include the absence of
paid staff working in Milwaukee, few connections with the
Milwaukee medical community, and the large number of
clinical practices and health plans.
Funding for WARN exceeded levels for other state-
based programs on antimicrobial drug resistance, but it
was far lower than the funding level for some other public
education campaigns. Annual funding for WARN staffing,
programs, and materials (excluding indirect costs and eval-
uation activities) was ≈$238,000–$342,000. By compari-
son, Wisconsin receives ≈$10 million in state funding and
$1.1 million in federal funding each year for smoking pre-
vention programs (Maureen Busalacchi, pers. comm.).
WARN funding for education on antimicrobial resistance
was not sufficient to conduct a widespread and sustained
media campaign, although whether such a campaign
would have led to further reductions in antimicrobial use is
not known.
One other published study reported the effect of inter-
ventions promoting appropriate antimicrobial drug use in a
large, highly populated area. In Knox County, Tennessee, a
12-month multifaceted campaign was conducted in 1997
and early 1998 (34). The clinician intervention included
professional presentations, distribution of pediatric princi-
ples of judicious antimicrobial drug use (35), and newslet-
ter articles. Patient and public education included
distribution of print materials, news media coverage, and
public service announcements. In the Medicaid managed
care program, antimicrobial drug prescribing for respirato-
ry illness declined 19% in Knox County and 8% in the
control counties compared to the previous year (interven-
tion attributable effect of 11%, p<0.001). The Knox
County intervention was smaller in scale and shorter in
duration than WARN, and the generalizability to non-
Medicaid populations is unknown.
Evaluating large-scale, multifaceted educational pro-
grams such as WARN has several limitations. The control
population in Minnesota was not isolated, and educational
materials and messages may have diffused into the control
area from a variety of sources. For example, during the
WARN follow-up period, national guidelines on appropri-
ate antimicrobial use were published and endorsed by the
Centers for Disease Control and Prevention and major pro-
fessional organizations (35–37). WARN also reached lim-
ited populations in Minnesota: radio advertisements
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physicians received the WARN satellite broadcasts on
appropriate antimicrobial drug use. In addition, efforts
within Minnesota to improve prescribing of antimicrobial
drugs increased during the follow-up period, particularly
during 2002 and 2003. A single state may not be the opti-
mal comparison population, and Minnesota in particular
has a highly educated population and a proactive public
health infrastructure with strong ties to the healthcare
delivery system. As a result, the improvements in antimi-
crobial drug prescribing within Minnesota may have been
greater than those in many other states. Finally, the com-
mercial prescribing data used for the WARN evaluation
did not include any information on visits or diagnoses. We
therefore cannot determine if the declines in antimicrobial
prescribing in Wisconsin and Minnesota were associated
with a declining rate of visits for acute respiratory illness
or if the rate of prescribing declined for specific diagnoses.
The centralized development of WARN programs and
materials facilitated statewide distribution, but it also lim-
ited the level of clinician involvement at the local level.
Direct, face-to-face communication with physicians was
rarely possible. In contrast, practice-level interventions
have shown modest success, and we speculate that these
focused, participatory interventions may promote physi-
cian behavior change more directly than a mass education
campaign such as WARN. However, WARN succeeded in
changing physicians’ knowledge and attitudes regarding
appropriate antimicrobial drug use, and WARN materials
were widely used by primary care clinicians throughout
the state. In a survey of primary care clinicians, 90% of
respondents had heard of WARN, and 70% of those had
used WARN materials for patient education (38). Models
of behavior change suggest that changes in prescribing
behavior are preceded by important cognitive changes that
proceed in stepwise fashion (39). Improvements in knowl-
edge and beliefs among both physicians and patients may
therefore be markers of progress, which may facilitate the
future success of provider-level interventions developed
by clinics and managed care organizations in Wisconsin. 
Increased funding for state-level educational cam-
paigns to promote appropriate antimicrobial drug use does
not appear warranted by the results of this evaluation.
However, the combined effect of national guidelines for
appropriate use of such drugs, increasing attention by the
media and professional organizations, and the Centers for
Disease Control and Prevention national campaign may
have contributed to the observed trend toward declining
antimicrobial use. Progress toward decreasing inappropri-
ate use is being made in many states, although antimicro-
bial prescribing rates remain excessive for bronchitis, and
use of broad-spectrum antimicrobial drugs is increasing
nationally (22,27,33). State and local organizations should
consider a balanced approach that includes limited
statewide educational activities with increasing emphasis
on local, provider-level interventions and policy develop-
ment. These activities might include academic detailing by
physician opinion leaders, feedback on antimicrobial pre-
scribing performance (including Health Plan Employer
Data and Information Set measures), and economic incen-
tives for careful antimicrobial use. These strategies may
have the greatest effect if implemented as quality improve-
ment initiatives in collaboration with the leadership of
health plans and clinic organizations. Ongoing assessment
of prescribing trends and rates of antimicrobial drug resist-
ance will be needed to measure the ultimate effect of these
efforts.
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